KeyBank National Association
RNAC icon

KeyBank National Association’s Cartesian Therapeutics RNAC Stock Holding History

KeyBank National Association’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-378
Closed -$176K – 1023
2018
Q3 		$176K Sell
378
-106
-22% -$42.6K ﹤0.01% 1014
2018
Q2 		$193K Hold
484
– – ﹤0.01% 995
2018
Q1 		$148K Hold
484
– – ﹤0.01% 1009
2017
Q4 		$143K Buy
+484
New +$211K ﹤0.01% 1012

Other funds holding RNAC

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KeyBank National Association's RNAC Position: Q4 2018 in Review

KeyBank National Association sold out of Cartesian Therapeutics (RNAC) in Q4 2018, closing a stake of 378 shares — an estimated $176K sold.

KeyBank National Association first reported a position in RNAC in Q4 2017 and held it in 4 quarters. The position peaked at $193K in Q2 2018. 54 funds tracked by Wall St. Rank hold RNAC as of Q4 2018.

  • KeyBank National Association reported no remaining Cartesian Therapeutics position as of Q4 2018 after selling out during the quarter.
  • KeyBank National Association sold 378 Cartesian Therapeutics shares in Q4 2018, an estimated $176K.
  • KeyBank National Association first reported a position in Cartesian Therapeutics in Q4 2017 and held it in 4 quarters.
  • KeyBank National Association's Cartesian Therapeutics position peaked at $193K in Q2 2018.
  • 54 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2018.

Based on KeyBank National Association's 13F filing for Q4 2018, filed 30 Jan 2019.